‘Magnetic pulse therapy may help treat depression’

London, May 10: A non-invasive and drug-free magnetic therapy could help thousands of people - doomed to a life of depression - kiss their blues away.
 Results from tests on more than severely depressed 300 patients found 58 percent achieved a positive response while more than a third went into remission.
 Researchers from the University of California (Los Angeles), US, were testing the Food and Drug Administration-approved NeuroStar TMS Therapy, which works by beaming magnetic pulses through the skull. These trigger small electrical charges that spark brain cells to fire.
 Ian Cook from California, who led the study, said: "The NeuroStar TMS not only reduces the symptomatic suffering of patients, but lessens the disability of depression with important implications for these individuals' ability to return to functioning effectively at home, in the workplace, and in the community."
 During each half-hour session the patient was placed under a treatment coil as big as a fist. It sent a pulsed magnetic field an inch under the scalp to the prefrontal cortex, the ante cingulate cortex and the limbic system, three brain areas thought to regulate mood, the Daily Mail reports.
 The magnetic field is similar in strength to that created by an MRI machine and sparks off very small electrical currents within the brain. This stimulates neuron activity thought to provide relief from depression.
 Anti-depressants are released into the blood, which can cause widespread physical side-effects such as hot flushes and nausea. However, supporters of NeuroStar say because it's a targeted therapy it only causes mild scalp pain.
 After an average of five weeks of NeuroStar treatment, the percentage of patients reporting extreme problems with anxiety and depression decreased by 42.2 percent.
 H. Brent Sovason from the Stanford University, said: "These data reinforce the clinical efficacy of the TMS therapy as a viable option for patients living with major depression who have not achieved or maintained symptom improvement with oral anti-depressants." IANS

Lastupdate on : Thu, 10 May 2012 21:30:00 Makkah time
Lastupdate on : Thu, 10 May 2012 18:30:00 GMT
Lastupdate on : Fri, 11 May 2012 00:00:00 IST




  • del.icio.us
  • StumbleUpon
  • Digg
  • TwitThis
  • Mixx
  • Technorati
  • Facebook
  • NewsVine
  • Reddit
  • Google
  • LinkedIn
  • YahooMyWeb
  • Print News
  • YahooMyWeb

Enter the Security code exactly as you see it in the image security code is CaSe SeNsItIvE(Cookies must be enabled)
  • MORE FROM HEALTH

  • Kashmir

SKIMS to have sarai for patients, attendants

Will Ease Stress: Dr Zargar

MANZOOR-UL-HASSAN

Srinagar, May 10: Management of Sher-e-Kashmir Institute of Medical Sciences (SKIMS) Soura has started the construction work on Rs 11 crore sarai (resting place) for the attendants of patients visiting More



  • Srinagar City

GOVT WAKES UP TO PARKING MESS IN CITY CENTRE

ERSTWHILE KMD BUS STAND WALL DEMOLISHED AFTER 17 YEARS

GK CITY CORRESPONDENT

Srinagar, May 10: As if the authorities had been sleeping all these years that despite the growing traffic mess they couldn’t identify a “blunder” on their part of having failed to remove a concrete wall More




  • Jammu

JK REELS UNDER ACUTE POWER SHORTAGE

Energy Banking, Shutdown Of Salal Power Station Blamed

ASHWANI LANGEH

Jammu, May 10: Jammu and Kashmir is reeling under acute electricity crisis due to shutdown of the Salal Hydro Electric Power Station Reasi and routing of 200 Mega Watts of electricity to other states under More



  • South Asia

Indo-Pak next Siachen talks on June 11-12

REZAUL H LASKAR\PTI

Islamabad, May 10: India and Pakistan will hold their next round of talks on the military standoff on Siachen glacier in Islamabad during June 11-12 against the backdrop of renewed calls from the Pakistani More



  • Health

First ever pill to beat HIV under FDA consideration

London, May 10: Truvada, the first ever pill to beat HIV -- a breakthrough in the 30-year-old war against AIDS epidemic -- is under active consideration of the US Food and Drug Administration (FDA) for More



ADD
Designed Developed and Maintaned By Imobisoft Ltd /Algosol Software Solutions